Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Joel Oger"'
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
Myasthenia gravis (MG) is a heterogeneous condition, characterized by autoantibodies (Abs) that target functionally important structures within neuromuscular junctions (NMJ), thus affecting nerve-to-muscle transmission. MG patients are more often now
Externí odkaz:
https://doaj.org/article/8363828479334dc68afde0734db5c3af
Autor:
Joel Oger, Joshua D Green, Bryan J Traynor, Richard J Barohn, Michael Benatar, Emanuela Bartoccion, Derrick Blackmore, Manisha Chopra, Andrea Corse, Mazen M Dimachkie, Amelia Evoli, Julaine Florence, Miriam Freimer, James F Howard, Theresa Jiwa, Henry J Kaminski, John T Kissel, Wilma J Koopman, Bernadette Lipscomb, Michelanglo Maestri, Mariapaola Marino, Janice M Massey, April McVey, Michelle M Mezei, Michael W Nicolle, Robert M Pascuzzi, Mamatha Pasnoor, Alan Pestronk, Carlo Provenzano, Roberta Ricciardi, David P Richman, Julie Rowin, Donald B Sanders, Zaeem Siddiqi, Aimee Soloway, Gil I Wolfe, Charlie Wulf, Daniel B Drachman
Publikováno v:
BMJ Open, Vol 10, Iss 9 (2020)
Objectives To approximate the rate of familial myasthenia gravis and the coexistence of other autoimmune disorders in the patients and their families.Design Retrospective cohort study.Setting Clinics across North America.Participants The study includ
Externí odkaz:
https://doaj.org/article/0145aad817a242af8725bc4e583792df
Autor:
Kate Tilling, Michael Lawton, Neil Robertson, Helen Tremlett, Feng Zhu, Katharine Harding, Joel Oger, Yoav Ben-Shlomo
Publikováno v:
Health Technology Assessment, Vol 20, Iss 81 (2016)
Background: The ability to better predict disease progression represents a major unmet need in multiple sclerosis (MS), and would help to inform therapeutic and management choices. Objectives: To develop multilevel models using longitudinal data on d
Externí odkaz:
https://doaj.org/article/d0a52efe78274103a0634f5342a0d0dd
Autor:
Mona Alkhawajah, Joel Oger
Publikováno v:
Multiple Sclerosis International, Vol 2011 (2011)
For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique character
Externí odkaz:
https://doaj.org/article/2c7fb28e353742909c9f1fe094dd1515
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 1 (2008)
Basic disease-modifying treatment for relapsing forms of active multiple sclerosis (MS) is now available in many countries with high prevalence rates, for this chronic inflammatory disease of the central nervous system. Several lines of evidence supp
Externí odkaz:
https://doaj.org/article/6537eea633a14563af27228c830d812f
Autor:
Adnan Al-Araji, MB, Joel Oger, MD
The Multiple Sclerosis International Foundation estimates that over 2.5 million people worldwide have multiple sclerosis. Throughout developed countries, increased attention has been paid to this disorder, due in large part to advanced imaging techno
Autor:
Zaeem A. Siddiqi, Robert M. Pascuzzi, Mazen M. Dimachkie, David P. Richman, Richard J. Barohn, Srikanth Muppidi, Michael Benatar, Julaine Florence, M Marino, Michelanglo Maestri, Vinay Chaudhry, Theresa Jiwa, Joshua D. Green, Roberta Ricciardi, Wilma J. Koopman, Joel Oger, Bernadette Lipscomb, Daniel B. Drachman, Manisha Chopra, Amelia Evoli, Derrick Blackmore, Julie Rowin, Gil I. Wolfe, Donald B. Sanders, Michelle M. Mezei, Carlo Provenzano, Henry J. Kaminski, Andrea M. Corse, Aimee Soloway, John T. Kissel, Alan Pestronk, Janice M. Massey, Emanuela Bartoccion, Miriam Freimer, Michael W. Nicolle, Charlie Wulf, April McVey, James F. Howard, Mamatha Pasnoor, Bryan J. Traynor
Publikováno v:
BMJ Open, Vol 10, Iss 9 (2020)
BMJ open, vol 10, iss 9
BMJ Open
BMJ open, vol 10, iss 9
BMJ Open
ObjectivesTo approximate the rate of familial myasthenia gravis and the coexistence of other autoimmune disorders in the patients and their families.DesignRetrospective cohort study.SettingClinics across North America.ParticipantsThe study included 1
Autor:
Year Ltf Investigators, David Kb Li, Stuart D. Cook, Eva-Maria Wicklein, R. Koelbach, Dawn Langdon, Christoph Pohl, Douglas S. Goodin, Marcelo Kremenchutzky, Gary Cutter, Timothy O'Donnell, Anthony T. Reder, Anthony Traboulsee, Joel Oger
Publikováno v:
Multiple Sclerosis Journal. 25:837-847
Background: Long-term follow-up from the randomized trial of interferon beta-1b (IFNB-1b) permitted the assessment of different definitions of no evidence of disease activity (NEDA) for predicting long-term outcome in multiple sclerosis (MS). Objecti
Publikováno v:
Journal of the Neurological Sciences. 429:118853
Publikováno v:
Neuroepidemiology. 54(2)
Background: Lifespan is 6–10 years shorter in multiple sclerosis (MS), but the reasons remain unclear. Using linked clinical- and population-based administrative health databases, we compared cause-specific mortality in an MS cohort to the general